The study examined the effects of autologous BCMA-targeted mRNA CAR-T cell therapy in patients with generalized myasthenia gravis in a randomized, placebo-controlled phase 2b trial.[6] Infusion of CAR‑T cells selectively removed plasma cells with high BCMA expression that produce antibodies, thereby remodeling the systemic immune environment.[1][2] Changes in dendritic cell populations and plasma cell composition have also been noted, suggesting a broader modification of the B-cell and plasma cell repertoire.[1][2] Patients treated with Descartes-08 had a higher proportion of clinical responders (on the MGC and MG-ADL scales) at month 3 compared to placebo after six weekly infusions.[6] Improvement in disease severity in treated patients persisted in most subjects up to 12 months after a single treatment cycle.[1][3][6] The safety profile of the therapy was favorable, with no need for lymphodepleting chemotherapy and no serious unexpected toxicities related to CAR‑T treatment reported.[1][3][6] Overall, exploratory biomarker analysis supports that targeting BCMA mRNA by CAR‑T cells results in a specific intervention against pathogenic plasma cells in myasthenia gravis.[1][2][6]